

## Dynamic MRI assays of endothelial permeability for the non-invasive differentiation of tumors with high from tumors with low VEGF-activity

C. C. Cyran<sup>1</sup>, B. Sennino<sup>2</sup>, Y. Fu<sup>3</sup>, V. Rogut<sup>3</sup>, B. Chaopathomkul<sup>3</sup>, D. M. Shames<sup>3</sup>, M. F. Wendland<sup>3</sup>, D. M. McDonald<sup>2</sup>, and R. C. Brasch<sup>3</sup>


<sup>1</sup>Department of Clinical Radiology, University Hospitals Munich - Grosshadern, Munich, Germany, <sup>2</sup>Comprehensive Cancer Center, Cardiovascular Research Institute, and Department of Anatomy, University of California San Francisco, San Francisco, California, United States, <sup>3</sup>Radiology, University of California San Francisco, San Francisco, California, United States

**Purpose:** To evaluate dynamic MRI assays of endothelial permeability for their potential to differentiate tumors with high intrinsic vascular endothelial growth factor (VEGF) activity from tumors with low VEGF-activity by correlating dynamic MRI assays of endothelial permeability with immunohistochemical measurements of VEGF on a tumor-by-tumor basis.


**Methods and Material:** Subcutaneous tumor xenografts were grown in athymic rats ( $n=13$ ) from two poorly differentiated, estrogen-receptor-negative human breast cancer cell lines; MDA-MB-231 ( $n=5$ ) with a high level of intrinsic VEGF-activity and MDA-MB-435 ( $n=8$ ) with a low level of intrinsic VEGF-activity. Dynamic contrast-enhanced MRI was performed at 2.0T using the macromolecular contrast agent albumin-(Gd-DTPA)<sub>27</sub> (1). Quantitative estimates of tumor microvessel permeability ( $K^{PS}$ ;  $\mu\text{l}/\text{min} \cdot 100\text{cm}^3$ ), based on a two-compartment kinetic model (2), were correlated with area-density (%) measurements of VEGF-immunoreactivity on tumor sections.

**Results:** Tumor endothelial permeability, assayed as the endothelial transfer coefficient  $K^{PS}$ , was significantly higher ( $p<0.03$ ) in MDA-MB-231 tumors ( $K^{PS}=58 \pm 30.9 \mu\text{l}/\text{min} \cdot 100\text{cm}^3$ ) than in MDA-MB-435 tumors ( $K^{PS}=24 \pm 8.4 \mu\text{l}/\text{min} \cdot 100\text{cm}^3$ ,  $p<0.05$ ). Correspondingly, VEGF area-density in MDA-MB-231 tumors was significantly higher ( $27.3 \pm 2.2\%$ ) than in MDA-MB-435 human breast cancer xenografts ( $10.5 \pm 0.5\%$ ,  $p<0.05$ ). Individual measurements for the two groups did not overlap. The correlation between  $K^{PS}$  values and measurements of VEGF area-density was significant ( $r=0.73$ ,  $p<0.01$ ).

**Conclusion:** Dynamic MRI assays of endothelial permeability have the potential to non-invasively assess VEGF-activity in tumors and could be clinically applicable to define the suitability of patients for VEGF-inhibiting anti-angiogenic drug therapy.



**Figure (A).** Graph showing the correlation,  $r = 0.73$ ,  $p < 0.01$ , for each examined MDA-MB-435 and MDA-MB-231 tumor, between the MRI-assayed endothelial transfer coefficient  $K^{PS}$  ( $\mu\text{L} \cdot \text{min}^{-1} \cdot 100 \text{cm}^{-3}$ ) and the immunohistochemically-assessed VEGF-area density (%). All values of VEGF area density greater than 20% are from MDA-231 tumors. Solid line denotes the best fit.



**Figure (B, C)** Confocal microscopic images of MDA-MB-435 and MDA-MB-231 tumors, stained for VEGF (red) and blood vessels (green), showing the relatively low expression of VEGF in MDA-MB-435 tumor (B) and the high expression of VEGF in MDA-MB-231 tumor (C). Scale bar: 120  $\mu\text{m}$  in (B, C).

### References:

1. Van Dijke CF et al Acad Radiol 9 (Suppl 1) 2002; 257–260.
2. Cyran CC et al J Magn Reson Imaging. 2008; 27(3):581-9.